Delivery Order 75N91019D00022-75N91023F00001
Active Awarded Last action
- Contract number
- 75N91023F00001
- Awardee
-
The Institute For Cancer Research UEI FF1XVJMDYVR1 Part of Temple University-Of The Commonwealth System Of Higher Education
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,038,958
Award facts
- Contract value 100% obligated
- $1,038,958.00 Current and potential, with all options
- Completion date 82% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Philadelphia, PA 19111, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Original award | $1,038,958 |
About this award
The National Cancer Institute awarded a firm fixed-price delivery order valued at $1,038,958 to The Institute For Cancer Research (ICR), a non-profit subsidiary of Temple University, on July 10, 2023, for research on colorectal cancer prevention using urolithin A in rodent cancer models. The work will be performed in Philadelphia, Pennsylvania, with a completion date of July 9, 2027. This task order was issued without set-aside designation and falls under ICR's larger $149.995 million Indefinite Delivery Contract with NCI for the PREVENT Preclinical Drug Development Program, which supports structured drug and vaccine development from discovery through clinical translation stages.
The research supports NCI's cancer prevention initiatives by evaluating a potential chemopreventive agent through preclinical efficacy studies. As part of the PREVENT program's three technical pools—Preclinical Efficacy and Biomarkers, Preclinical Services for Product Development and Manufacturing, and Preclinical Toxicology and Pharmacology Testing—this task order leverages ICR's extensive expertise in cancer biology, preclinical drug development, and biomarker identification. The work will contribute to NCI's broader efforts to identify and validate promising cancer prevention candidates before advancing them toward clinical development.
Quick answers
Who was awarded contract 75N91023F00001?
75N91023F00001 was awarded to The Institute For Cancer Research by National Cancer Institute (National Institutes of Health) on July 10, 2023.
How much is contract 75N91023F00001 worth?
The government has obligated $1,038,958 on 75N91023F00001.
Is contract 75N91023F00001 an order under another contract?
Yes. 75N91023F00001 is a delivery order under 75N91019D00022, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91023F00001 competed?
The extent of competition for 75N91023F00001 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award